LONDON, Oct 8 (Reuters) - Pfizer ( PFE ) and its German
partner BioNTech on Tuesday won their attempt to
invalidate two of rival CureVac's ( CVAC ) patents at London's
High Court.
Pfizer ( PFE ) and BioNTech had filed their lawsuit in September
2022 over patents relating to messenger RNA (mRNA) technology,
which underpins Pfizer ( PFE ) and BioNTech's COVID-19 vaccine.